Clinical study of Qi-Shen Yi-Qi dropping pill in the treatment of acute myocardial infarction patient with Qi-Xu Xue-Yu zhen

注册号:

Registration number:

ITMCTR2000002922

最近更新日期:

Date of Last Refreshed on:

2020-01-15

注册时间:

Date of Registration:

2020-01-15

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

芪参益气滴丸治疗急性心肌梗死恢复期气虚血瘀证患者临床研究方案

Public title:

Clinical study of Qi-Shen Yi-Qi dropping pill in the treatment of acute myocardial infarction patient with Qi-Xu Xue-Yu zhen

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于CDKN2A 通路的益气活血法治疗心肌梗死恢复期气虚血瘀证表观遗传调控研究

Scientific title:

Epigenetic regulation of qi-deficiency and blood-stasis syndrome in conescence of myocardial infarction by supplementing Qi-Xu Xue-Yu zhen based on CDKN2A pathway

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000029136 ; ChiMCTR2000002922

申请注册联系人:

刘志超

研究负责人:

谷旭放

Applicant:

Zhichao Liu

Study leader:

Xufang Gu

申请注册联系人电话:

Applicant telephone:

+86 18222286377

研究负责人电话:

Study leader's telephone:

+86 13821724681

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

821202536@qq.com

研究负责人电子邮件:

Study leader's E-mail:

guxf218@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

天津市河北区增产道69号

研究负责人通讯地址:

天津市河北区增产道69号

Applicant address:

69 Zengchan Road, Hebei District, Tianjin, China

Study leader's address:

69 Zengchan Road, Hebei District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津中医药大学

Applicant's institution:

Tianjin University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2019-051-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

天津中医药大学第二附属医院医学伦理委员会

Name of the ethic committee:

Medical ethics committee of the second affiliated hospital of tianjin university of Chinese medici

伦理委员会批准日期:

Date of approved by ethic committee:

2019/12/26 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津中医药大学第二附属医院

Primary sponsor:

The second affiliated hospital of tianjin university of traditional Chinese medicine

研究实施负责(组长)单位地址:

天津市河北区增产道69号

Primary sponsor's address:

69 Zengchan Road, Hebei District, Tianjin, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津市

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津中医药大学第二附属医院

具体地址:

天津市河北区增产道69号

Institution
hospital:

The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Address:

69 Zengchan Road, Hebei District

经费或物资来源:

国家自然科学基金委

Source(s) of funding:

National natural science foundation of China

研究疾病:

急性心肌梗死

研究疾病代码:

Target disease:

acute myocardial infarction

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

上市后药物

Post-marketing clinical trial

研究目的:

评价芪参益气滴丸治疗急性心肌梗死恢复期气虚血瘀证患者的临床疗效,探究急性心肌梗死恢复期气虚血瘀证患者的表观遗传学机制

Objectives of Study:

To evaluate the clinical effect of qishengyiqi drop pill on patients with qi deficiency and blood stasis syndrome in convalescent period of acute myocardial infarction, and to explore the epigenetic mechanism of qi deficiency and blood stasis syndrome in convalescent period of acute myocardial infarction

药物成份或治疗方案详述:

试验组:芪参益气滴丸+基础药物治疗(ACEI、β受体阻滞剂、DAPT 等)。 对照组:基础药物治疗(ACEI、β受体阻滞剂、DAPT 等)。 健康人组:不采取任何药物干预(仅作为与急性心肌梗死恢复期患者的基因检测的参照)。

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)年龄 35-70 岁,性别数量均衡; (2)发生急性心肌梗死,经临床诊疗后 15 天至 3 个月的患者; (3)受试者近 15 天内病情稳定; (4)中医证型辨为气虚血瘀 1)主症:表现为胸闷、胸痛 2)次症 ①血瘀证: 口唇、面色或爪甲紫暗;舌质紫、暗或有瘀点、瘀斑;舌底脉络粗张; 脉涩或沉弦、弦迟。 ②气虚症: 心悸气短;神倦乏力;易于汗出,动则加重;面色晄白;舌质淡;舌边有齿痕;脉弱。 (5)自愿签署知情同意书。 (6)健康人组受试者纳入: ①性别均衡,年龄在 35 至 70 岁之间的各个年龄段选取男、女受试者各 1 人,共 10 人。 ②近 3 个月内未服用任何药物、未参加其他临床试验。 ③无冠心病、代谢性疾病及其他疾病。 ④自愿签署知情同意书。

Inclusion criteria

1. aged 35-70 years old; 2. patients with acute myocardial infarction, 15 days to 3 months after clinical diagnosis and treatment; 3. the subject's condition was stable within 15 days; 4. TCM syndrome type is identified as qi deficiency and blood stasis: (1) main symptoms: chest tightness, chest pain 2) secondary symptoms (blood stasis: purple and dark lips, complexion or claw plate;The tongue is purple or dark or has petechiae or ecchymosis;The veins under the tongue are coarse; Pulse acerbity or sink string, string late; (2) gas deficiency: palpitations and shortness of breath; God languishes; Easy to sweat, moving is aggravated;Complexion white; Tongue is weak; Teeth marks on the side of tongue; Weak pulse; 5. voluntarily sign the informed consent; 6. healthy group: aged 35 to 70 years old; Did not take any drugs or participate in other clinical trials within 3 months; no coronary heart disease, metabolic disease and other diseases; voluntary signing of informed consent.

排除标准:

(1)先天性心脏病、心脏瓣膜病、动脉瘤、过敏体质及对药物过敏、代谢性疾病(糖尿病 除外)、严重感染、严重的肝肾功能异常以及有脑血管疾病病史的个体; (2)2 年内有怀孕计划的育龄期女性(育龄期女性定义为所有有怀孕生理能力的女性) 及已怀孕女性; (3)前 3 个月内参加过任何药物临床试验者; (4)研究者判断患者生存期不超过 6 个月者; (5)严重的神经系统疾病(阿茨海默病,帕金森综合征进展期),下肢残缺或聋哑患者; (6)既往有肿瘤病史或现患肿瘤者,或病理检查证实有癌前病变; (7)通过检查(体格检查,或 X 光检查或 B 超检查或其他手段),发现体内有恶性肿块,或发现有内分泌活性、影响心功能或内分泌功能的增生腺体或腺瘤的患者,如嗜铬细胞瘤, 甲状腺肿大)等; (8)根据研究者判断,患者不能完成本研究或不能遵守本研究的要求(由于管理方面的 原因或其它特殊原因)。 (9)健康人组受试者排除标准: ①怀孕女性。 ②前 3 个月有服用药物记录、参加过其他临床试验。 ③根据研究者判断,患者不能完成本研究或不能遵守本研究的要求(由于管理方面的原 因或其它特殊原因)。

Exclusion criteria:

(1) patients with congenital heart disease, heart valve disease, aneurysm, allergic constitution, metabolic diseases (except diabetes), severe infection, severe liver and kidney dysfunction, and a history of cerebrovascular disease;(2) women of child-bearing age who have planned to become pregnant within 2 years (defined as all women of child-bearing age who are physically capable of becoming pregnant) and women who have become pregnant; (3) those who have participated in any drug clinical trial within the first 3 months; (4) the researcher judged that the survival of the patients should not exceed 6 months; (5) patients with severe neurological diseases (alzheimer's disease, progressive stage of Parkinson's disease), lower limb disability or deaf-mute; (6) patients with a previous history of tumor or current tumor, or confirmed by pathological examination to have precancerous lesions; (7) patients who have been found to have a malignant mass by examination (physical examination, X-ray examination or b-ultrasound examination or other means), or who have been found to have endocrine activity, hyperplasia glands or adenoma affecting heart or endocrine function, such as pheochromocytoma, goiters, etc.; (8) in the judgment of the investigator, the patient is unable to complete the study or comply with the requirements of the study (due to management reasons or other special reasons); (9) healthy subjects: pregnant women; Drug use in the first 3 months; participated in other clinical trials; In the judgment of the investigator, the patient is unable to complete the study or comply with the requirements of the study (due to management reasons or other special reasons).

研究实施时间:

Study execute time:

From 2020-03-01

To      2022-03-01

征募观察对象时间:

Recruiting time:

From 2020-03-01

To      2021-06-30

干预措施:

Interventions:

组别:

试验组

样本量:

36

Group:

Experimental group

Sample size:

干预措施:

芪参益气滴丸联合常规西药治疗

干预措施代码:

Intervention:

Qi-Shen Yi-Qi drop pills combined with conventional western medicine treatment

Intervention code:

组别:

对照组

样本量:

36

Group:

control group

Sample size:

干预措施:

常规西药治疗

干预措施代码:

Intervention:

Conventional western medicine treatment

Intervention code:

样本总量 Total sample size : 72

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津中医药大学第二附属医院

单位级别:

三甲医院

Institution/hospital:

The second affiliated hospital of tianjin university of traditional Chinese medicine

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

二维超声心动图

指标类型:

主要指标

Outcome:

two dimensional echocardiogram

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

量表

指标类型:

主要指标

Outcome:

scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心电图

指标类型:

主要指标

Outcome:

Electrocardiograph

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

全血样本

组织:

静脉采血

Sample Name:

blood

Tissue:

venous blood collection

人体标本去向

使用后保存

说明

Fate of sample 

Preservation after use

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 35
Min age years
最大 70
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机方法:采用信封法进行随机分组,在密闭不透光信封内装有 A 或 B 两个字母,共72 封(编号 1-72),规定字母 A 数试验组,B为对照组,受试者随机抽取一封,由第三方人员(机构)保留分组结果,记录后将信封再次密封。 数字采用随机数字表法选取。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random method: the envelope method was used for random grouping. Two letters A or B were placed in the sealed light-proof envelope, with A total of 72 letters (no. 1-72). According to the letter A number test group, B was the control group.The Numbers are selected by the random number table meth

盲法:

指定一个研究者负责只对受试者进行纳入、出组、不良事件监察等,指定另一个研究者对受试者进行访视及病例报告表记录,指定一名药品管理员只对试验组受试者进行发药及药品回收,并且保留由第三方人员(机构)所提供的分组结果,便于记录药物使用情况。规定指定人员各自与受试者单独联系,指定人员之间相互不能联系。如果某受试者发生严重不良事件经研究者评估符合紧急揭盲条件,研究者联系第三方人员(机构)获取受试者编号后,打开信封,获取该受试者的用药具体信息。

Blinding:

Specify a researcher is responsible for only the subjects into and out of the group, adverse event monitoring, etc., specify another researchers for the subjects to conduct supervision and case report form records, specify a drug administrator only the experimental group subjects in medicine and drugs, and retain staff by third parties (institutions) provided by the group as a result, easy to record drug usage.It is stipulated that the designated person shall contact with the subject separately, and the designated person shall not contact with each other.If a subject has a serious adverse event and is evaluated by the investigator as meeting the criteria for emergency unblinding, the investigator contacts a third party (institution) to obtain the subject number, then opens the envelope to obtain the specific medication information of the subject.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

天津中医药大学第二附属医药理基地保存资料,可申请查阅

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The second affiliated medical science base of tianjin university of traditional Chinese medicine can apply for inspection

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例报告表由研究者填写,每个入选病例(包括脱落病例)必须完成病例报告表。经过检查后的病例报告表,应核查签字后,将病例报告表及时送交临床试验数据管理员。移交后病例报告表的内容不再做修改。对于完成的病例报告表在研究者、数据管理员之间的传递应由专门的记录,记录需妥善保存。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The case report form is completed by the investigator and must be completed for each enrolled case (including shed case).The case report form after examination shall be checked and signed and sent to the clinical trial data manager in time.The contents of the case report form will not be modified after handover.The transfer of the completed case report form between the investigator and the data manager shall be made by special records, which shall be kept properly.

数据管理委员会:

Data Managemen Committee:

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above